Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x100px
All >

Deals > Switzerland

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Switzerland or involving Swiss organisations.

Total search results: 909 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
ExpressionEdits–Redalpine: investment, 202405 seed financing round totalling $13m incl co-lead investor Redalpine 2024-05-29
Limula–SEVERAL: investment, 202405 seed financing round CHF6.2m led by LifeX Ventures 2024-05-21
Cutiss–Gisev: investment, 202405 financing round Series C 1st closing totalling CHF25m incl existing + co-lead investor Gisev 2024-05-17
Cutiss–IBSA Pharma: VitiCell medical device, 202405 license existent from IBSA Pharma 2024-05-17
Cutiss–SEVERAL: investment, 202405 financing round Series C 1st closing CHF25m co-led by Gisev Familiy Office + US family represented by Shiloh 2024-05-17
Cutiss–Shiloh Advisors: investment, 202405 financing round Series C 1st closing totalling CHF25m incl new + co-lead investor Shiloh/US family office 2024-05-17
Takeda–AC Immune: Abeta immunotherapy, 202405– excl ww license + option agreem for ACI-24.060 with $100m upfront + $2.1b milestones 2024-05-13
BioVersys–GSK: investment, 202403 financing round Series C extension totalling CHF12.3m incl investor GSK as part of collab 2024-05-07
BioVersys–SEVERAL: investment, 202403 financing round Series C extension CHF12.3m bringing total Series C to CHF44.9m 2024-05-07
GSK–BioVersys: alpibectir, 202405– collab expansion to speed up development to treat tuberculosis 2024-05-07
Memo Therapeutics–Adjuvant Capital: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Adjuvant Capital 2024-05-07
Memo Therapeutics–Bellevue: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Pureos Bioventures 2024-05-07
Memo Therapeutics–Eurazeo: investment, 202405 financing round Series C extension totalling CHF20m incl new investor Kurma Partners 2024-05-07
Memo Therapeutics–Fresenius: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor FMCV 2024-05-07
Memo Therapeutics–GF Group: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor GF Group 2024-05-07
Memo Therapeutics–ICR: public relations, 202405 service existent ICR Consilium is media contact 2024-05-07
Memo Therapeutics–Redalpine: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Red Alpine 2024-05-07
Memo Therapeutics–Schroders: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Schroders Capital 2024-05-07
Memo Therapeutics–SEVERAL: investment, 202405 financing round Series C extension CHF20m bringing total Series C to CHF45m 2024-05-07
Memo Therapeutics–Verve Capital Partners: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Verve Ventures 2024-05-07
Memo Therapeutics–Vesalius Biocapital: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Vesalius 2024-05-07
Memo Therapeutics–Ysios Capital: investment, 202405 financing round Series C extension totalling CHF20m incl new investor Ysios Capital 2024-05-07
Memo Therapeutics–Zürcher Kantonalbank: investment, 202405 financing round Series C extension totalling CHF20m incl existing investor Swisscanto 2024-05-07
Mariana Oncology–Novartis: investment, 202405– acquisition $1b upfront + $750m milestones of Mariana Oncology by Novartis 2024-05-02
Novartis–PeptiDream: drug discovery, 202404– collab expansion $180m upfront + $2.71b milesotnes discovery peptides for conjugation to radionuclides 2024-04-30
FundaMental Pharma–Novartis: investment, 202404 investment €2.7m??? by new investor NVF brings total seed financing to €12.7m 2024-04-11
Hemotune–SEVERAL: investment, 202403 financing round Series B2 CHF14m led by Belmondo 2024-03-25
Volumina Medical–SEVERAL: investment, 202403 financing round Series A $21m with existing + new investors 2024-03-25
Nouscom–Angelini: investment, 202403 investment €7m from Angelini Ventures as Series C extension bringing total round to €75.8m 2024-03-21
Capstan Therapeutics–Novartis: investment, 202403 financing round Series B totalling $175m incl existing + co-investor Novartis Venture Fund 2024-03-20
Perspix Biotech–BioCopy: investment, 20403 acquisition of Perspix Biotech GmbH by BioCopy AG + renamed to BioCopy Analytix GmbH 2024-03-20
Roche–Lonza: investment, 202403– acquisition $1.2b in cash of Genentech biologics manufacturing facility in California from Roche 2024-03-20
Alithea Genomics–Novalis Biotech: investment, 202303 seed financing round extension totalling CHF2.8m incl existing + lead investor Novalis Biotech AF 2024-03-14
Alithea Genomics–SEVERAL: investment, 202303 seed financing round extension CHF2.8m led by Novalis Biotech Acceleration Fund 2024-03-14
Alithea Genomics–TechU Ventures: investment, 202303 seed financing round extension totalling CHF2.8m incl new + co-investor TechU Ventures 2024-03-14
Tubulis–BioMedPartners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor BioMedPartners 2024-03-14
Tubulis–Nextech: investment, 202403 financing round Series B2 totalling €128m incl co-lead investor Nextech Invest Ltd 2024-03-14
Tubulis–Occident: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Occident 2024-03-14
Firefly Bio–Versant Ventures: investment, 202402c emerges with financing round Series A totalling $94m incl co-lead investor Versant Venture 2024-02-15
CRISPR Therapeutics–EcoR1 Capital: investment, 202402 registered direct offering totalling $280m incl new + co-lead investor EcoR1 Capital 2024-02-13
CRISPR Therapeutics–SEVERAL: investment, 202402 registered direct offering $280m at $71.5/share led by EcoR1 Capital + SR One 2024-02-13
CRISPR Therapeutics–SR One: investment, 202402 registered direct offering totalling $280m incl co-lead investor SR One 2024-02-13
Roche–PathAI: AI-based diagnostics, 202402– collab expansion excl developm of AI-enabled ditial patholoty algorythms for CDx with RTD 2024-02-13
MorphoSys–Novartis: investment, 202402– acquisition of MorphoSys voluntary public takeover offer €2.7b in cash at €68/share 2024-02-05
Silence Therapeutics–Nextech: investment, 202402 private placement totalling $120m incl investor Nextech Invest Ltd 2024-02-05
Chemspeed–Bruker: investment, 202401– acquisition €na of Chemspeed Technology AG by Bruker 2024-01-25
Stalicla–OTHER: credit, 202401 credit facility $3.8m as part of Series B 1st closing 2024-01-16
Stalicla–SEVERAL: investment, 202401 financing round Series B 1st closing of $13.6m led by SPRIM Global Investments Pte Ltd 2024-01-16
Stalicla–SPRIM Global: investment, 202401 financing round Series B 1st closing totalling $13.6m incl lead investor SPRIM Global Investments Pte Ltd 2024-01-16
CRISPR Therapeutics–JPMorgan Chase: investor conference, 202401 supply service CRISPR Tx presents at JP Morgan Healthcare Conference 2024 2024-01-09
Calypso Biotech–Novartis: investment, 202401– acquisition $250m upfront + $175m milestones by Novartis SIGNED 2024-01-08
Novartis–Argo Biopharma: RNAi therapeutics, 202401– two license ex-China + collab agreements $185m upfront + $3.98b milestones + royalties 2024-01-07
GlycoEra–BMS: investment, 202401 financing round Series A extension with new investor BMS 2024-01-05
SanReno Therapeutics–Novartis: investment, 202401 acquisition remaining shares by Novartis to become wholly-owend subsidiary 2024-01-05
Caresyntax–MTIP: investment, 2023 financing round incl $15m from MTIP II Fund 2023-12-31
Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter 2023-12-23
AC Immune–Avidity Partners: investment, 202312 underwritten offering totalling $50.05m incl co-investor Avidity Partners 2023-12-15
AC Immune–BVF Partners: investment, 202312 underwritten offering totalling $50.05m incl lead investor BVF Partners LP 2023-12-15
AC Immune–Redmile Group: investment, 202312 underwritten offering totalling $50.05m incl co-investor Redmile Group 2023-12-15
AC Immune–SEVERAL: investment, 202312 underwritten offering $50.05m led by BVF Partners with 14.3m common shares at $3.5/share 2023-12-15
AC Immune–StemPoint Capital: investment, 202312 underwritten offering totalling $50.05m incl co-investor StemPoint Capital LP 2023-12-15
Vandria–+ND Capital: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl lead investor +ND Capital 2023-12-14
Vandria–OTHER: investment, 202312 emerges from stealth with financing round Series A totalling CHF18m incl small syndicate of HNW private investors 2023-12-14
Vandria–SEVERAL: investment, 202312 emerges from stealth with financing round Series A CHF18m led by +ND Capital 2023-12-14
Odyssey Therapeutics–HBM: investment, 202312 financing round Series C totalling $101m incl existing + co-investor HBM Healthcare Investments 2023-12-05
Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche 2023-12-04
T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF450m by Boehringer Ingelheim 2023-11-22
Evolva–Lallemand: investment, 202311– acquisition of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG 2023-11-21
Nouscom–5AM Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor 5AM Ventures 2023-11-14
Nouscom–Andera Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Andera Partners 2023-11-14
Nouscom–EQT: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor EQT Life Sciences 2023-11-14
Nouscom–France (govt): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Bpifrance InnoBio 2 Fund 2023-11-14
Nouscom–Indaco Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Indaco Venture Partners 2023-11-14
Nouscom–Merck (DE): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor M Ventures 2023-11-14
Nouscom–Panakès Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Panakès Partners 2023-11-14
Nouscom–Revelation Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Relevation Partners 2023-11-14
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures 2023-11-14
Nouscom–Versant Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor Versant Ventures 2023-11-14
Nouscom–XGen Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Xgen Ventures 2023-11-14
Novartis–GenScript: CAR-T cell therapies, 202311– license excl ww $100m upfront + $1.01b milestones + royalties for DLL CAR-Ts Legend Biotech 2023-11-13
Sallea–Venture Kick: grant, 202311 startup award CHF150k from Venture Kick 2023-11-13
Memo Therapeutics–Adjuvant Capital: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Adjuvant Capital 2023-11-02
Memo Therapeutics–Bellevue: investment, 202311 financing round Series C totalling CHF25m incl new + lead investor Pureos Bioventures 2023-11-02
Memo Therapeutics–Fresenius: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Fresenius Medical Care Ventures 2023-11-02
Memo Therapeutics–GF Group: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor GFGroup 2023-11-02
Memo Therapeutics–Redalpine: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Red Alpine 2023-11-02
Memo Therapeutics–Schroders: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Schroders Capital 2023-11-02
Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV 2023-11-02
Memo Therapeutics–Verve Capital Partners: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Verve Ventures 2023-11-02
Memo Therapeutics–Vesalius Biocapital: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Vesalius Biocapital 2023-11-02
Memo Therapeutics–Zürcher Kantonalbank: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Swisscanto 2023-11-02
LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund 2023-10-09
MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker 2023-10-04
Kranus Health–CSS (CH): investment, 202310 financing round Series A expansion totalling approx $8.5m incl new + co-lead investor SwissHealth Ventures 2023-10-02
MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m 2023-10-01
Alentis Therapeutics–Kyan Technologies: drug discovery technology, 202309– collab using Optim.AI + PD3D technologies for Claudin-1 expression research 2023-09-29
Nagi Bioscience–Excellis: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-investor Excellis Holding 2023-09-28
Nagi Bioscience–imec: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor imec.xpand 2023-09-28
Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand 2023-09-28
Nagi Bioscience–Verve Capital Partners: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor Verve Ventures 2023-09-28
1 2 3 4 5 6 7 8 9 10  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x300px

» top